Pharmaron Beijing Co., Ltd. Share Price
Equities
300759
CNE100003JW4
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.71 CNY | -0.29% |
|
+5.02% | -28.54% |
| 08-28 | Pharmaron Beijing Posts Nearly 42% Higher Profit in H1; Stocks Up By 4% | MT |
| 08-28 | Nomura Adjusts Pharmaron Beijing's Price Target to 29.73 Yuan From 31.41 Yuan, Keeps at Buy | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
| Capitalization | 33.14B 4.66B 356B | P/E ratio 2024 * |
21.1x | P/E ratio 2025 * | 19.6x |
|---|---|---|---|---|---|
| Enterprise value | 51.09B 7.18B 549B | EV / Sales 2024 * |
2.86x | EV / Sales 2025 * | 2.5x |
| Free-Float |
48.11% | Yield 2024 * |
1% | Yield 2025 * | 1.07% |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
| 1 day | -0.29% | ||
| 1 week | +5.02% | ||
| Current month | +3.60% | ||
| 1 month | -0.96% | ||
| 3 months | +4.28% | ||
| 6 months | -9.72% | ||
| Current year | -28.54% |
1 week
19.15
21.44
1 month
18.4221.44
Current year
17.7028.90
1 year
17.7037.00
3 years
17.70100.84
5 years
17.70108.71
10 years
4.08108.71
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
FOU | Founder | 55 | 30/06/04 |
Bei Zheng
FOU | Founder | 57 | 30/06/04 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 30/06/04 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 30/06/04 |
Bei Zheng
FOU | Founder | 57 | 30/06/04 |
Ke Xin Yang
CHM | Chairman | 62 | 30/06/04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.17% | 1 M€ | -20.08% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.29% | +5.02% | -25.42% | -76.10% | 4.67B | ||
| -0.44% | +1.72% | +11.95% | -28.77% | 46.38B | ||
| -0.56% | -5.05% | +8.69% | -7.81% | 43.26B | ||
| +1.31% | +5.58% | +25.45% | +42.91% | 33.62B | ||
| -15.58% | -10.17% | -37.31% | -84.28% | 30.56B | ||
| +2.57% | +2.84% | +31.01% | -22.43% | 29.37B | ||
| +2.34% | -4.00% | +14.93% | +15.15% | 24B | ||
| -0.69% | -1.79% | +53.61% | +63.99% | 15.4B | ||
| -1.44% | -0.30% | +0.25% | -42.58% | 11.66B | ||
| +1.85% | -1.92% | +21.89% | +83.55% | 10.35B | ||
| Average | -1.07% | +0.91% | +10.50% | -5.64% | 24.93B | |
| Weighted average by Cap. | -1.37% | +0.60% | +11.44% | -8.43% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 12.62B 1.77B 136B | 14.13B 1.99B 152B |
| Net income | 1.75B 245M 18.76B | 1.89B 266M 20.33B |
| Net Debt | 3.11B 436M 33.37B | 2.73B 383M 29.3B |
More financial data
* Estimated data
Employees
0
Calendar
23/10/2024
- Q3 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/24 | 20.71 ¥ | -0.29% | 18,364,060 |
| 11/09/24 | 20.77 ¥ | +3.90% | 20,861,530 |
| 10/09/24 | 19.99 ¥ | -0.84% | 19,986,120 |
| 09/09/24 | 20.16 ¥ | +4.08% | 24,349,610 |
| 06/09/24 | 19.37 ¥ | -2.17% | 8,401,728 |
End-of-day quote Shenzhen S.E., September 11, 2024
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
20.71CNY
Average target price
22.63CNY
Spread / Average Target
+9.28%
- Stock Market
- Equities
- 300759 Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition